comparemela.com
Latest Breaking News On - Claudin 18 - Page 1 : comparemela.com
ASCO GI 2023: SPOTLIGHT Study
The SPOTLIGHT study results presented at the 2023 ASCO GI Cancers Symposium are explored by Dr Marshall.
Johnl-marshall
Gi-cancer
Junction-protein
Zolbetuximab
Claudin-18
Monoclonal-antibody
Her2-overexpression
Progression-free-survival
Overall-survival
Ngs-testing
Immunohistochemistry-tests
vimarsana © 2020. All Rights Reserved.